Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Condition(s)
Neuroblastoma

Age Group
0-9 years 10-17 years 18-26 years

Phase(s)
1

Biological treatment cell Biological
Patient Derived CD171 specific CAR T cells expressing EGFRt
Trial Summary

Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the investigators are attempting to use T cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR). The CAR enables the T cell to recognize and kill the neuroblastoma cell through the recognition of CD171, a protein expressed of the surface of the neuroblastoma cell in patients with neuroblastoma. This is a phase 1 study designed to determine the maximum tolerated dose of the CAR+ T cells.

Ages: 18 Months to 26 Years
Condition: Neuroblastoma, Ganglioneuroblastoma
Status
Recruiting
Location(s)
Seattle Children's Hospital, Seattle, WA
Contact
Navin Pinto, MD
206-987-2106